GCP
RPRX

GSA Capital Partners’s Repros Therapeutics Inc. RPRX Stock Holding History

GSA Capital Partners’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-27,931
Closed -$27K – 2101
2016
Q1 		$27K Buy
+27,931
New +$27.2K ﹤0.01% 1618

Other funds holding RPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
AIA
Allegis Investment Advisors Idaho Falls, Idaho $326M AUM 10.36% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
BIM
Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return

GSA Capital Partners's RPRX Position: Q2 2016 in Review

GSA Capital Partners sold out of Repros Therapeutics Inc. (RPRX) in Q2 2016, closing a stake of 27,931 shares — an estimated $27K sold.

GSA Capital Partners first reported a position in RPRX in Q1 2016 and held it in 1 quarter. The position peaked at $27K in Q1 2016. 43 funds tracked by Wall St. Rank hold RPRX as of Q2 2016.

  • GSA Capital Partners reported no remaining Repros Therapeutics Inc. position as of Q2 2016 after selling out during the quarter.
  • GSA Capital Partners sold 27,931 Repros Therapeutics Inc. shares in Q2 2016, an estimated $27K.
  • GSA Capital Partners first reported a position in Repros Therapeutics Inc. in Q1 2016 and held it in 1 quarter.
  • GSA Capital Partners's Repros Therapeutics Inc. position peaked at $27K in Q1 2016.
  • 43 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q2 2016.

Based on GSA Capital Partners's 13F filing for Q2 2016, filed 4 Aug 2016.